CREAPHARM BIOSERVICES obtient de l’ANSM l’autorisation d’ouverture d’établissements pharmaceutiques et étend ses activités aux médicaments de thérapie innovante
AUTHORIZED AS A PHARMACEUTICAL COMPANY BY FRENCH REGULATORY AUTHORITIES (ANSM), CREAPHARM BIOSERVICES EXPANDS ITS SCOPE TO INCLUDE ADVANCED THERAPY MEDICINAL PRODUCTS
On the occasion of its third aniversary, the biobank which integrated CREAPHARM GROUP as CREAPHARM BIOSERVICES, got its Manufacturer’s Authorisation from the French National Agency for Medicines and Health Products (ANSM*) on August 21th 2023.
DELPHARM & CREAPHARM annoncent avoir uni leurs forces pour offrir le meilleur accompagnement à HMNC Brain Health
DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial.
DELPHARM and CREAPHARM announced today that they have combined their expertises to synergistically support HMNC Brain Health, a global clinical-stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry.